News
JNJ
155.04
-0.28%
-0.43
J&J gets FDA breakthrough therapy status for nipocalimab in Sjogren's
Seeking Alpha · 23h ago
Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High Prevalence, For Which No Approved Advanced Treatments Are Available
Benzinga · 23h ago
Johnson & Johnson: FDA grants nipocalimab Breakthrough Therapy designation
TipRanks · 23h ago
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
PR Newswire · 23h ago
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
NASDAQ · 1d ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
NASDAQ · 1d ago
Weekly Report: what happened at JNJ last week (1104-1108)?
Weekly Report · 1d ago
Cartesian Therapeutics: Uncertainty Remains
Seeking Alpha · 2d ago
67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs
Seeking Alpha · 2d ago
5 Relatively Secure And Cheap Dividend Stocks - November 2024: Yields Up To 9%
Seeking Alpha · 3d ago
Notable Two Hundred Day Moving Average Cross - JNJ
NASDAQ · 4d ago
J&J seeks approval of Darzalex for early-stage multiple myeloma
Seeking Alpha · 4d ago
Johnson & Johnson Seeks Approval Of Darzalex Faspro In US, Darzalex In EU For Myeloma Treatment
NASDAQ · 4d ago
Johnson & Johnson submits applications for new indications for Darzalex
TipRanks · 4d ago
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
The Motley Fool · 4d ago
Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?
Barchart · 4d ago
What's Next For Merck Stock After An Upbeat Q3?
NASDAQ · 4d ago
Should You Pick Bristol Myers Squibb Stock At $55?
NASDAQ · 4d ago
My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%
Seeking Alpha · 4d ago
QUS: Mixing Value, Quality And Volatility For An Average Outcome
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).